Seminars in thrombosis and hemostasis最新文献_第10页

Modulating Immune Responses: The Double-Edged Sword of Platelet CD40L. 调节免疫反应：血小板 CD40L 的双刃剑

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-08 DOI: 10.1055/s-0044-1791512

Gerd Bendas, Martina Gobec, Martin Schlesinger

{"title":"Modulating Immune Responses: The Double-Edged Sword of Platelet CD40L.","authors":"Gerd Bendas, Martina Gobec, Martin Schlesinger","doi":"10.1055/s-0044-1791512","DOIUrl":"https://doi.org/10.1055/s-0044-1791512","url":null,"abstract":"The CD40-CD40L receptor ligand pair plays a fundamental role in the modulation of the innate as well as the adaptive immune response, regulating monocyte, T and B cell activation, and antibody isotype switching. Although the expression and function of the CD40-CD40L dyad is mainly attributed to the classical immune cells, the majority of CD40L is expressed by activated platelets, either in a membrane-bound form or shed as soluble molecules in the circulation. Platelet-derived CD40L is involved in the communication with different immune cell subpopulations and regulates their functions effectively. Thus, platelet CD40L contributes to the containment and clearance of bacterial and viral infections, and additionally guides leukocytes to sites of infection. However, platelet CD40L promotes inflammatory cellular responses also in a pathophysiological context. For example, in HIV infections, platelet CD40L is supportive of neuronal inflammation, damage, and finally HIV-related dementia. In sepsis, platelet CD40L can induce extensive endothelial and epithelial damage resulting in barrier dysfunction of the gut, whereby the translocation of microbiota into the circulation further aggravates the uncontrolled systemic inflammation. Nevertheless, a distinct platelet subpopulation expressing CD40L under septic conditions can attenuate systemic inflammation and reduce mortality in mice. This review focuses on recent findings in the field of platelet CD40L biology and its physiological and pathophysiological implications, and thereby highlights platelets as vital immune cells that are essential for a proper immune surveillance. In this context, platelet CD40L proves to be an interesting target for various inflammatory diseases. However, either an agonism or a blockade of CD40L needs to be well balanced since both the approaches can cause severe adverse events, ranging from hyperinflammation to immune deficiency. Thus, an interference in CD40L activities should be likely done in a context-dependent and timely restricted manner.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies. 抗磷脂综合征的血栓形成：抗磷脂抗体实验室检测的当前视角与挑战》（Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies）。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-07 DOI: 10.1055/s-0044-1791699

Katrien M J Devreese

{"title":"Thrombosis in Antiphospholipid Syndrome: Current Perspectives and Challenges in Laboratory Testing for Antiphospholipid Antibodies.","authors":"Katrien M J Devreese","doi":"10.1055/s-0044-1791699","DOIUrl":"https://doi.org/10.1055/s-0044-1791699","url":null,"abstract":"Antiphospholipid syndrome (APS) diagnosis hinges on identifying antiphospholipid antibodies (aPL). Currently, laboratory testing encompasses lupus anticoagulant (LA), anticardiolipin (aCL), and anti-β2-glycoprotein I antibodies (aβ2GPI) IgG or IgM, which are included in the APS classification criteria. All the assays needed to detect aPL antibodies have methodological concerns. LA testing remains challenging due to its complexity and susceptibility to interference from anticoagulant therapy. Solid phase assays for aCL and aβ2GPI exhibit discrepancies between different assays. Antibody profiles aid in identifying the patients at risk for thrombosis through integrated interpretation of all positive aPL tests. Antibodies targeting domain I of β2-glycoprotein and antiphosphatidylserine-prothrombin antibodies have been evaluated for their role in thrombotic APS but are not yet included in the APS criteria. Detecting these antibodies may help patients with incomplete antibody profiles and stratify the risk of APS patients. The added diagnostic value of other methodologies and measurements of other APS-associated antibodies are inconsistent. This manuscript describes laboratory parameters useful in the diagnosis of thrombotic APS and will concentrate on the laboratory aspects, clinical significance of assays, and interpretation of aPL results in the diagnosis of thrombotic APS.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":""},"PeriodicalIF":3.6,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142393077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibitors of Polyphosphate and Neutrophil Extracellular Traps. 多磷酸盐和中性粒细胞胞外陷阱抑制剂。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2023-05-16 DOI: 10.1055/s-0043-1768936

Sreeparna Vappala, Stephanie A Smith, Jayachandran N Kizhakkedathu, James H Morrissey

{"title":"Inhibitors of Polyphosphate and Neutrophil Extracellular Traps.","authors":"Sreeparna Vappala, Stephanie A Smith, Jayachandran N Kizhakkedathu, James H Morrissey","doi":"10.1055/s-0043-1768936","DOIUrl":"10.1055/s-0043-1768936","url":null,"abstract":"The contact pathway of blood clotting has received intense interest in recent years as studies have linked it to thrombosis, inflammation, and innate immunity. Because the contact pathway plays little to no role in normal hemostasis, it has emerged as a potential target for safer thromboprotection, relative to currently approved antithrombotic drugs which all target the final common pathway of blood clotting. Research since the mid-2000s has identified polyphosphate, DNA, and RNA as important triggers of the contact pathway with roles in thrombosis, although these molecules also modulate blood clotting and inflammation via mechanisms other than the contact pathway of the clotting cascade. The most significant source of extracellular DNA in many disease settings is in the form of neutrophil extracellular traps (NETs), which have been shown to contribute to incidence and severity of thrombosis. This review summarizes known roles of extracellular polyphosphate and nucleic acids in thrombosis, with an emphasis on novel agents under current development that target the prothrombotic activities of polyphosphate and NETs.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"970-977"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10651799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9477797","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prone Position and the Risk of Venous Thrombosis in COVID-19 Patients with Respiratory Failure. 俯卧位与 COVID-19 呼吸衰竭患者静脉血栓形成的风险。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2024-05-11 DOI: 10.1055/s-0044-1786735

Giuseppe Lippi, Camilla Mattiuzzi, Emmanuel J Favaloro

引用次数: 0

Contact Activation: Where Thrombosis and Hemostasis Meet on a Foreign Surface, Plus a Mini-editorial Compilation ("Part XVI"). 接触活化：血栓与止血在异物表面相遇，外加小型编辑汇编（"第 XVI 部分"）。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2024-05-17 DOI: 10.1055/s-0044-1786751

Helen H Vu, Owen J T McCarty, Emmanuel J Favaloro

引用次数: 0

Heparins May Not Be the Optimal Anticoagulants for Sepsis and Sepsis-Associated Disseminated Intravascular Coagulation. 肝素可能不是败血症和败血症相关弥散性血管内凝血的最佳抗凝剂。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2024-05-11 DOI: 10.1055/s-0044-1786754

Toshiaki Iba, Julie Helms, Takaaki Totoki, Jerrold H Levy

{"title":"Heparins May Not Be the Optimal Anticoagulants for Sepsis and Sepsis-Associated Disseminated Intravascular Coagulation.","authors":"Toshiaki Iba, Julie Helms, Takaaki Totoki, Jerrold H Levy","doi":"10.1055/s-0044-1786754","DOIUrl":"10.1055/s-0044-1786754","url":null,"abstract":"Historically, heparin has had the longest historical use as an anticoagulant and continues this day to be the primary therapeutic option for preventing thrombosis and thromboembolism in critically ill hospitalized patients. Heparin is also used to treat sepsis and sepsis-associated disseminated intravascular coagulation (DIC) in various countries. However, the efficacy and safety of heparin for this indication remains controversial, as adequately powered randomized clinical studies have not demonstrated as yet a survival benefit in sepsis and sepsis-associated DIC, despite meta-analyses and propensity analyses reporting improved outcomes without increasing bleeding risk. Further, activated protein C and recombinant thrombomodulin showed greater improvements in outcomes compared with heparin, although these effects were inconclusive. In summary, further research is warranted, despite the ongoing clinical use of heparin for sepsis and sepsis-associated DIC. Based on Japanese guidelines, antithrombin or recombinant thrombomodulin may be a preferable choice if they are accessible.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"1012-1018"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140909365","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Factor XII Structure-Function Relationships. 因素十二结构-功能关系。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2023-06-05 DOI: 10.1055/s-0043-1769509

Aleksandr Shamanaev, Maxim Litvak, Ivan Ivanov, Priyanka Srivastava, Mao-Fu Sun, S Kent Dickeson, Sunil Kumar, Tracey Z He, David Gailani

{"title":"Factor XII Structure-Function Relationships.","authors":"Aleksandr Shamanaev, Maxim Litvak, Ivan Ivanov, Priyanka Srivastava, Mao-Fu Sun, S Kent Dickeson, Sunil Kumar, Tracey Z He, David Gailani","doi":"10.1055/s-0043-1769509","DOIUrl":"10.1055/s-0043-1769509","url":null,"abstract":"Factor XII (FXII), the zymogen of the protease FXIIa, contributes to pathologic processes such as bradykinin-dependent angioedema and thrombosis through its capacity to convert the homologs prekallikrein and factor XI to the proteases plasma kallikrein and factor XIa. FXII activation and FXIIa activity are enhanced when the protein binds to a surface. Here, we review recent work on the structure and enzymology of FXII with an emphasis on how they relate to pathology. FXII is a homolog of pro-hepatocyte growth factor activator (pro-HGFA). We prepared a panel of FXII molecules in which individual domains were replaced with corresponding pro-HGFA domains and tested them in FXII activation and activity assays. When in fluid phase (not surface bound), FXII and prekallikrein undergo reciprocal activation. The FXII heavy chain restricts reciprocal activation, setting limits on the rate of this process. Pro-HGFA replacements for the FXII fibronectin type 2 or kringle domains markedly accelerate reciprocal activation, indicating disruption of the normal regulatory function of the heavy chain. Surface binding also enhances FXII activation and activity. This effect is lost if the FXII first epidermal growth factor (EGF1) domain is replaced with pro-HGFA EGF1. These results suggest that FXII circulates in blood in a \"closed\" form that is resistant to activation. Intramolecular interactions involving the fibronectin type 2 and kringle domains maintain the closed form. FXII binding to a surface through the EGF1 domain disrupts these interactions, resulting in an open conformation that facilitates FXII activation. These observations have implications for understanding FXII contributions to diseases such as hereditary angioedema and surface-triggered thrombosis, and for developing treatments for thrombo-inflammatory disorders.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"937-952"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10696136/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9577462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2024 Eberhard F. Mammen Award Announcements: Part I-Most Popular Articles. 2024 年埃伯哈德-F-马门奖公告：第一部分-最受欢迎的文章。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2024-03-08 DOI: 10.1055/s-0044-1782197

Emmanuel J Favaloro

引用次数: 0

Plasma Kallikrein as a Forgotten Clotting Factor. 血浆 Kallikrein 是一种被遗忘的凝血因子。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2023-04-18 DOI: 10.1055/s-0043-57034

Katherine J Kearney, Henri M H Spronk, Jonas Emsley, Nigel S Key, Helen Philippou

{"title":"Plasma Kallikrein as a Forgotten Clotting Factor.","authors":"Katherine J Kearney, Henri M H Spronk, Jonas Emsley, Nigel S Key, Helen Philippou","doi":"10.1055/s-0043-57034","DOIUrl":"10.1055/s-0043-57034","url":null,"abstract":"For decades, it was considered that plasma kallikrein's (PKa) sole function within the coagulation cascade is the activation of factor (F)XII. Until recently, the two key known activators of FIX within the coagulation cascade were activated FXI(a) and the tissue factor-FVII(a) complex. Simultaneously, and using independent experimental approaches, three groups identified a new branch of the coagulation cascade, whereby PKa can directly activate FIX. These key studies identified that (1) FIX or FIXa can bind with high affinity to either prekallikrein (PK) or PKa; (2) in human plasma, PKa can dose dependently trigger thrombin generation and clot formation independent of FXI; (3) in FXI knockout murine models treated with intrinsic pathway agonists, PKa activity results in increased formation of FIXa:AT complexes, indicating direct activation of FIX by PKa in vivo. These findings suggest that there is both a canonical (FXIa-dependent) and non-canonical (PKa-dependent) pathway of FIX activation. These three recent studies are described within this review, alongside historical data that hinted at the existence of this novel role of PKa as a coagulation clotting factor. The implications of direct PKa cleavage of FIX remain to be determined physiologically, pathophysiologically, and in the context of next-generation anticoagulants in development.","PeriodicalId":21673,"journal":{"name":"Seminars in thrombosis and hemostasis","volume":" ","pages":"953-961"},"PeriodicalIF":3.6,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10000934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Next, Next-Generation of Sequencing, Promising to Boost Research and Clinical Practice. 下一代测序技术，有望促进研究和临床实践。

IF 3.6 2区医学

Seminars in thrombosis and hemostasis Pub Date : 2024-10-01 Epub Date: 2024-05-11 DOI: 10.1055/s-0044-1786756

Kishore R Kumar, Mark J Cowley, Ryan L Davis

引用次数: 0